Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 30: 1254-1257, 1984;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Babson, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Babson, A. L.

Clinical Chemistry, Vol 30, 1254-1257, Copyright © 1984 by American Association for Clinical Chemistry

A new endogenous immunoenzyme assay for prostatic acid phosphatase evaluated

AL Babson

I evaluated the performance of the "ORTHO PAP-IA," an endogenous immunoenzyme assay for prostatic acid phosphatase. The procedure is based on double-antibody precipitation of the antigen, followed by quantification of its enzymic activity. The antibodies are in large excess, to speed the reactions and minimize sensitivity to variations in assay conditions. Enzymic activity is measured via an extremely sensitive colorimetric reaction, the analytical sensitivity of which exceeds that of radioimmunoassay. Absorbance is linearly related to activity concentration up to an absorbance of 4.0, and only a single calibration standard is required. Within-run CV was less than 2%, between-run CV about 4%. Neither individual blanks nor assay in duplicate is required. All reagents, including the enzyme standard, are stable solutions. Results correlated well with those by a standard radioimmunoassay (r = 0.993, n = 38).




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American Association for Clinical Chemistry.